AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06038435 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ayres Sensory Integration Therapy
Description: Sensory integration therapy will be applied.
Study NCT06038435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ayres Sensory Integration Therapy
Description: Sensory integration therapy will be applied.
Study NCT06006832 — intervention group
Intervention type: DRUG
Intervention: Steroid Drug
Description: Maintaining low-dose oral steroids
Study NCT06006832 — intervention group
Intervention type: OTHER
Intervention: Withdraw all immunosuppresants
Description: Withdraw all immunosuppresants
Study NCT06304285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: Acupuncture was performed according to the corresponding acupoint of the patient
Study NCT06304285 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture treatment
Description: The needle only touches the patient's skin and does not penetrate the skin
Study NCT06325839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HypnoBirthing training and oxytocin massage group
Description: HypnoBirthing training and oxytocin massage were applied for a total of 12 hours for 4 weeks with the experimental group.
Study NCT05286255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stromal Cells
Description: Intravenous MSCs 1.2-1.5 x 10\^6 cells/kg on Days 1 and 3 after study enrollment
Study NCT06191809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Ovarian Stimulation Protocol
Description: Ovarian Stimulation Process:~* Stimulate ovaries with FSH \& hMG (150-375 IU) starting day 2-3 of menstruation.~* Monitor response with ultrasound \& hormones (E2, LH, P4).~* GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5.~* PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1.~* Trigger ovulation when ≥2 follicles >17mm (Triptorelin, hCG, or rhCG).~* Oocyte retrieval 36-38 hours later (>10mm follicles aspirated).~Embryo Culture \& Monitoring:~* Fertilize with ICSI.~* Culture \& evaluate embryos (43-45 hours, day 3/5).~* Freeze all embryos.
Study NCT06462950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Do men and women differ in their reactions to the experimental conditions.
Description: Do men and women differ in their reactions to the experimental conditions.
Study NCT05375123 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound image acquisition
Description: Echocardiography: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS.~Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester (20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-41 weeks of gestation), 6 weeks and 3-6 months after delivery.~Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester (20 to 24 weeks of gestation).
Study NCT06434792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronpass Tab.
Description: Twice daily for 12 weeks
Study NCT06434792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily for 12 weeks
Study NCT05724264 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose CT of the Chest (LDCT) + Sampling for Biomarker Assays
Description: LDCT scan results will be reported based on the Lung-RADS classification. Participants will be stratified into various Lung-RADS groups based on the CT appearance and size of nodules. An alphanumeric Lung-RADS score will be assigned to each subject which will guide the downstream management of screened participants.~All subjects will be required to donate drawn blood samples (up to 30 ml) at every LDCT visit during screening surveillance, and at every LDCT/CT scan and/or biopsy visits during clinical surveillance for blood-based biomarker assays development and characterization. Subjects may also be asked to provide a sample of urine, saliva and breath for biomarker discovery.
Study NCT05543681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IGC-AD1-Active
Description: A non-sterile solution for oral administration.
Study NCT05543681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IGC-AD1-Placebo
Description: A non-sterile solution for oral administration similar in color and texture to the Active.
Study NCT05958342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Gluconate
Description: 1 gram calcium gluconate provided via intravenous or intraosseous access over approximately 2-5 minutes
Study NCT05958342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: 4 unit vasopressin bolus followed by vasopressin infusion at 0.04 U/min for eight hours
Study NCT05958342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: saline placebo volume matched to prehospital or in hospital phase
Study NCT05329363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PEPITS Programme
Description: The programme has three main phases:~Phase I: Introduction phase (Session 1) Phase II: Pathology and care work phase (Sessions 2 - 3 - 4) Phase III: Recovery and stepping stone phase (Sessions 5 - 6 - 7) The programme provides information, keys and new skills to the patient through 3 phases focusing on pathology and recovery.
Study NCT05329363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will receive the same psychiatric care as the experimental group except of the PEPITS programme.
Study NCT05436262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time fMRI with neurofeedback of motor imagery
Description: Participants undergo a real-time fMRI scan during which they are provided feedback regarding the accuracy of their motor imagery performance.
Study NCT06336083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: Participants will receive doppler ultrasound of the carotid arteries, and no other interventions studied
Study NCT05884476 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment-as-usual
Description: Veterans in the TAU-only control condition will remain engaged in their normal standard of mental health care throughout their participation in this study. Veterans in the TAU condition will have access to and receive referrals for any of the following services normally afforded to patients at this VA hospital: VA Office of Connected Care web-based training programs and mobile mental health applications; primary care appointments; PCMHI consultation; outpatient mental health individual and group therapies; psychiatry appointments; inpatient hospitalization in the event of a suicidal crisis during study participation; and post-discharge mental health follow-up appointments following inpatient hospitalization for medical or mental health reasons.
Study NCT05884476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re-Evaluating Suicidal Thoughts
Description: REST is a brief, computerized intervention designed to mitigate psychological inflexibility associated with the experience of suicidal ideation. Most individuals complete the intervention in under one hour. REST provides psychoeducation to correct common misconceptions about suicidal ideation and help Veterans de-catastrophize the occurrence and meaning of these thoughts. This includes information about the prevalence of suicidal ideation among Veterans, a conceptualization of suicidal ideation as a response to stress, normalizing emotional reactions to suicidal ideation, and framing suicidal ideation as thoughts and conjectures as opposed to truth and reality. These components were chosen to directly address emotional distress related to suicidal thoughts, which is central to the construct of psychological inflexibility. Veterans randomized to receive REST will have access to and be encouraged to utilize any and all of these options described in the TAU-only condition.
Study NCT06342180 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum uric acid level
Description: An amount of 2-3 ml of blood sample will be collected from the patients after 8-12 hours of fasting and will be kept frozen at -70 degrees to calculate the serum UA level.
Study NCT05069402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: diet with immunonutrients
Study NCT05069402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-protein
Description: Oral nutrition with high-protein content
Study NCT05069402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard ONS
Description: Oral nutrition with standard ingredients
Study NCT03809364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: START Together
Description: Behavioral intervention using a cognitive behavioral couple therapy (CBCT) framework designed to improve the couple's communication and problem-solving behavior.
Study NCT05416905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN-DBS
Description: The patients will be treated with deep brain electrode placement of STN target under local and general anesthesia. Switching the system on: the stimulator will be switched on 3 weeks after surgery to allow time for the brain edema and stun effect to wear off. Postoperative medication: The subject taking medication in the past will continue the medication. If the subject with no medication before, will be required not to take medication related to dystonia.
Study NCT05416905 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GPi-DBS
Description: The patients will be treated with deep brain electrode implantation of GPi target under local and general anesthesia. Except that the surgical target was GPi, the operation process, stimulator switch-on time, and postoperative medication were the same as those in the STN-DBS group.
Study NCT05448898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine CU Xiu Tang
Description: Oral Traditional Chinese Medicine CU Xiu Tang once a day and repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
Study NCT05448898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory Training
Description: repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
Study NCT04309825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transgastrostomal endoscopy
Description: Placement the endoscope through the g-tube port and not through the mouth of a patient undergoing an upper gi endoscopy
Study NCT04949958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Based Manual (Supervised)
Description: Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise, Exercise and Education. The exercise will be supervised while other component will be home based.
Study NCT04949958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Based Manual (Home Based)
Description: Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise and Education. All two components will be home based.
Study NCT04949958 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: General advice to be active
Study NCT05114525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: The survey questionnaire will include semi-structured questions about patient demographics and patient understanding of the risks and benefits of radiation, different treatment options, the treatment process, utility of visual aid presentation and information gathering preference using a semi-structured questionnaire
Study NCT06245122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS23546
Description: Tablets administered orally.
Study NCT04837859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: age 18-60: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT if PET positive resudues after the end of Tis or Tis-AVD age 60+: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT for all patients
Study NCT05096208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF (Group 1)
Description: RSV vaccine (RSVpreF)
Study NCT05096208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF (Group 2)
Description: RSV vaccine (RSVpreF)
Study NCT05096208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF (Group 3)
Description: RSV vaccine (RSVpreF)
Study NCT05096208 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04859790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Concerns Appraisal Retraining
Description: SCAR consists of an hour-long intervention session, followed by a 2-week-long EMI. During the hour-long intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety), discuss popular misconceptions they may have about publicly observable anxiety symptoms (e.g., people can tell I'm anxious by looking at me), and complete exposure exercises (e.g., practicing facing feared physical sensations such as sweating). During the EMI, participants will report on their social anxiety symptoms four times per day. When participants endorse elevated social anxiety during this time, they will receive a targeted message reminding them of the topics covered in the intervention session.
Study NCT06459050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dominant Limb Overcoming Isometric Conditioning Activity
Description: Each session involved performing 3 sets of 3-second overcoming isometric split squats with a 3-minute rest between sets as a conditioning activity performed by the dominant limb.
Study NCT05674591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Description: The CPT therapist will teach the patient about PTSD, depression, and anxiety, and outline the treatment regimen and rationale for its effectiveness. In the initial sessions, women will be asked to express their impact statements on the intimate partner violence to which they had been subjected. Women will be taught how to differentiate between events, thoughts, and emotions, as well as their interrelationships. Thoughts of self-blame and other misconceptions of the situation will be addressed using Socratic questioning. Women will be instructed on how to detect and counteract negative thoughts, as well as how to communicate more effectively. Women will be encouraged to evaluate negative thinking relating to five themes: safety, trust, power/control, self-esteem, and intimacy. During the final sessions, their impact statements on the violence to which they had been subjected will be altered to include emotional and cognitive insights obtained during the CPT.
Study NCT05764876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid Oral Tablet
Description: Oral tablet of linezolid 10mg/kg every 8 hours for 7 days.
Study NCT05764876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Oral Tablet
Description: Oral tablet of azithromycin 30mg/kg maximum 2gr single dose.
Study NCT06482905 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
Description: Safety Run-In: Dose:6×10\^7 CAR+ T cells~Cohort A Single delivery route(Multi-dose)、Cohort B Dual delivery route(Multi-dose)： 3+3 dose escalation design： Dose Level 1: 6×10\^7 CAR+ T cells Dose Level 2: 1.5×10\^8 CAR+ T cells Dose Level 3: 2.5×10\^8 CAR+ T cells
Study NCT06313489 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy of EPL tendon and muscle during the operation
Description: Biopsy of EPL tendon and muscle
Study NCT05363319 — intervention group
Intervention type: DRUG
Intervention: Cemiplimab
Description: solution for injection via intravenous (IV) infusion
Study NCT05363319 — intervention group
Intervention type: DRUG
Intervention: Platinum-based chemotherapy
Description: IV administration
Study NCT06471023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP1
Description: Vitamin C formulation 1, 1000 mg
Study NCT06471023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP2
Description: Vitamin C formulation 2, 1000 mg
Study NCT06471023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP3
Description: Vitamin C formulation 3, 1000 mg
Study NCT06471023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP4
Description: regular Vitamin C, 3000 mg
Study NCT06471023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: CP
Description: Vitamin C formulation 4, 1000 mg
Study NCT06471023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: RP
Description: regular Vitamin C, 1000 mg
Study NCT06311578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-87704916
Description: JNJ-87704916 will be administered as an intratumoral injection.
Study NCT06311578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.
Study NCT06459050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-dominant Limb Overcoming Isometric Conditioning Activity
Description: Each session involved performing 3 sets of 3-second overcoming isometric split squats with a 3-minute rest between sets as a conditioning activity performed by non-dominant limb.
Study NCT06251635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5Mg Oral Tablet
Description: Olanzapine capsules (2.5mg) will be administered during one research visit for each menstrual cycle phase. The dosing schedule is as follows:~1. Day 0- 5mg~2. Day 1- 10mg
Study NCT06251635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule during one research visit of each menstrual cycle phase.
Study NCT06251635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro 100 UNT/ML
Description: At each visit, participants will be given an intranasal insulin challenge (160 IU) to assess brain insulin signalling via MRI based assay.
Study NCT06251635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: At each visit, participants will be given an intranasal saline placebo (1.6 mL) in order to establish baseline brain insulin signalling via MRI based assay.
Study NCT05780177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Description: Participants in this arm will receive 4 sessions (20-60 minutes) of a brief behavioral treatment for insomnia called BBTI. Relaxation techniques are not a component of BBTI.
Study NCT05780177 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation Training (PMRT)
Description: Participants in this arm will receive 4 sessions (20-60 minutes) of progressive muscle relaxation training called PMRT.
Study NCT05874427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimedia informed consent
Description: A standard consent form on paper to explain the procedure, with an additional video to explain the procedure and risks.
Study NCT05874427 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard informed consent
Description: A standard consent form, written on paper, used to explain a procedure to a patient face-to-face by a physician.
Study NCT04381689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG FLU Vaccine Prefilled Syringe INJ.
Description: Teratect Prefilled Syringe Inj. 0.5mL
Study NCT04381689 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Tetra Pre-filled Syringe
Description: Fluarix Tetra Pre-filled Syringe 0.5mL
Study NCT04560972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT04560972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04560972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT04560972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protein Phosphatase 2A Inhibitor LB-100
Description: Given IV
Study NCT05169723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exertional respiratory activities
Description: participants will perform a series of exertional respiratory activities
Study NCT06458582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula
Description: The intervention involves administering High-Flow Nasal Cannula therapy to very preterm infants immediately after birth.
Study NCT05360160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNDX-5613
Description: Given by PO
Study NCT05360160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO
Study NCT05360160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Given by PO
Study NCT05292989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty Assessment
Description: Personalised (tailored) approach that includes assessment of frailty and structured information provided to the consumer